DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/kgh8nx/adhd_therapeutics) has announced the addition of the "ADHD Therapeutics Market to 2018 - New Diagnostic Parameters for Adult ADHD Offer Hope for Higher Rates of Treatment" report to their offering.
The ADHD therapeutics market is expected to show strong growth in Spain and Japan, with Compound Annual Growth Rates (CAGRs) of 8% and 15% respectively. However, the total revenues of these markets are still expected to be much lower than the largest market, the US, which is expected to reach $6,260m by 2018. This is due to the much higher diagnosis rates for both adults and children with ADHD in the US.
The report provides insights into the up-and-coming trends of the ADHD market in seven major markets: the US, the top five European countries (France, Germany, Italy, Spain and the UK) and Japan.
The report includes market forecasts to 2019, detailed pipeline analysis, in-depth profiling of major products and details of recent industry deals.
Products Mentioned
- Adderall XR (mixed amphetamine salt)
- Concerta (methylphenidate hydrochloride)
- Daytrana (methylphenidate transdermal patch)
- Focalin XR (dexmethylphenidate hydrochloride)
- Intuniv (guanfacine)
- Kapvay (clonidine hydrochloride)
- Strattera (atomoxetine hydrochloride)
- Vyvanse (lisdexamfetamine dimesylate)
Key Topics Covered:
- Tables & Figures
- ADHD Therapeutics Market to 2018 - Introduction
- ADHD Therapeutics: Market Characterization by Geography
- ADHD Therapeutics Market to 2018 - Competitive Landscape
- ADHD Therapeutics Market to 2018 - Product Pipeline Analysis
- ADHD Therapeutics Market to 2018 - Strategic Consolidations
- Appendix
For more information visit http://www.researchandmarkets.com/research/kgh8nx/adhd_therapeutics
